--- canonical_name: Cissus quadrangularis alternate_names: CQ, Hadjod, Asthisamharaka, Veldt Grape, Devil's Backbone, Adamant Creeper, Bone Setter, Pirandai, Vitis quadrangularis canonical_topic: Cissus quadrangularis for Health & Longevity short_topic_lc: cissus_quadrangularis creation_date: 2026-0628-0207 creator_ai_fullname: Opus 4.8 --- # Cissus quadrangularis for Health & Longevity

Evidence Review created on 06/28/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** CQ, Hadjod, Asthisamharaka, Veldt Grape, Devil's Backbone, Adamant Creeper, Bone Setter, Pirandai, Vitis quadrangularis ## Motivation *Cissus quadrangularis* (often sold as Hadjod or veldt grape) is a succulent vine from the grape family that has been used in traditional Indian and African medicine for centuries, primarily to speed the healing of broken bones — a use captured by its Sanskrit name, which means "bone setter." Its stems are rich in plant compounds such as flavonoids and plant sterols that are thought to act on bone-building cells and to calm inflammation. In modern use, the plant has moved beyond fracture care into the supplement market, where it is marketed for bone density, joint comfort in athletes, and weight management. A handful of small human trials and a few pooled analyses have begun to test these claims, while most of the supporting data still come from laboratory and animal work. Interest among health- and longevity-focused users centers on whether a low-cost botanical can meaningfully support the skeleton and joints as the body ages. This review examines the human and preclinical evidence on *Cissus quadrangularis* across bone health, joint pain, and metabolic measures, alongside its proposed mechanisms, safety profile, dosing patterns, and the gaps that remain in the research. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists high-level overviews and expert resources that introduce *Cissus quadrangularis* and its main uses for a general yet motivated audience. * [Cissus quadrangularis: Uses, Benefits, Side Effects, and Dosage](https://www.healthline.com/nutrition/cissus-quadrangularis) - Healthline A plain-language overview that summarizes the plant's traditional uses, the strength of the modern evidence for bone and joint health, typical dosing, and safety, making it a useful orientation for a non-specialist reader. * [Cissus quadrangularis L: A comprehensive multidisciplinary review](https://pubmed.ncbi.nlm.nih.gov/34181958/) - Bafna et al., 2021 A detailed narrative review of the botany, traditional uses, phytochemistry, pharmacology, and toxicology of the plant, providing the deepest single-source background on how its compounds are thought to work and which conditions have been studied. * [Cissus quadrangularis reduces joint pain in exercise-trained men: a pilot study](https://pubmed.ncbi.nlm.nih.gov/24113700/) - Bloomer et al., 2013 A primary human pilot study reporting a roughly 31% reduction in joint-pain scores after eight weeks of supplementation in active men, directly relevant to the joint-comfort claims that drive much of the supplement's popularity. * [Optimize & Control Your Brain Chemistry to Improve Health & Performance](https://www.hubermanlab.com/episode/optimize-and-control-your-brain-chemistry-to-improve-health-and-performance) - Andrew Huberman In this episode, Andrew Huberman discusses *Cissus quadrangularis* by name as a serotonin-supporting supplement, citing human data that it raises circulating serotonin, which situates the plant's lesser-known mood and well-being angle alongside its better-studied bone and metabolic uses. * [A short review on pharmacological activity of Cissus quadrangularis](https://pubmed.ncbi.nlm.nih.gov/33214745/) - Sundaran et al., 2020 A concise narrative review of the plant's reported pharmacological actions — analgesic, anti-inflammatory, antioxidant, and bone-related — useful as a quick map of where preclinical signals exist. *Note: Among the prioritized experts, only Andrew Huberman discusses* Cissus quadrangularis *by name (Huberman Lab Episode 80, included above); no by-name coverage was found from Rhonda Patrick, Peter Attia, Chris Kresser, or Life Extension Magazine, so the remaining entries draw on the best available eligible overviews and primary commentary.* ## Grokipedia [Cissus quadrangularis](https://grokipedia.com/page/Cissus_quadrangularis) The Grokipedia entry provides a broad, AI-fact-checked overview of the plant's botany, traditional uses, chemistry, and reported health effects, serving as a general orientation point. ## Examine [Cissus quadrangularis](https://examine.com/supplements/cissus-quadrangularis/) Examine's evidence-graded page summarizes the human and animal research on bone and joint health and weight management, making it one of the most rigorous independent overviews of where the data actually stand. ## ConsumerLab No dedicated ConsumerLab article or product test for *Cissus quadrangularis* was found. ConsumerLab focuses its independent testing on more widely sold supplement categories and does not currently appear to cover this botanical. ## Systematic Reviews This section lists systematic reviews and meta-analyses that pool the human evidence on *Cissus quadrangularis*. * [The effects of Cissus quadrangularis on bone-related biomarkers in humans: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/40707943/) - Na Takuathung et al., 2025 Pooling seven randomized trials in 354 participants, this analysis found that the plant significantly raised parathyroid hormone but did not change calcium, phosphorus, or alkaline phosphatase; the authors rated the certainty of evidence as very low across all measures. * [Efficacy and Safety of Cissus quadrangularis L. in Clinical Use: A Systematic Review and Meta-analysis of Randomized Controlled Trials](https://pubmed.ncbi.nlm.nih.gov/28165166/) - Sawangjit et al., 2017 This pooled analysis of nine trials (1,108 patients) reported benefit for bone-fracture pain and, for combination products only, meaningful reductions in body weight, blood lipids, and fasting blood sugar, while finding no advantage over comparators for hemorrhoids. * [Effectiveness of herbal medicines for weight loss: A systematic review and meta-analysis of randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/31984610/) - Maunder et al., 2020 A broad meta-analysis of 54 weight-loss trials that flagged *Cissus quadrangularis* among herbs showing statistically and clinically significant weight loss in a small number of studies, while cautioning that the underlying trials were few and of generally poor quality. * [A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity](https://pubmed.ncbi.nlm.nih.gov/19575486/) - Hasani-Ranjbar et al., 2009 An earlier systematic review of botanical anti-obesity agents that included *Cissus quadrangularis* among the candidates with preliminary supportive data, providing historical context for the weight-management research line. * [Evaluation of use and efficacy of African traditional medicine for metabolic syndrome: a systematic review](https://pubmed.ncbi.nlm.nih.gov/41520564/) - Altayyar et al., 2026 A recent systematic review of African traditional medicines for metabolic syndrome that situates *Cissus quadrangularis* within the wider evidence on plant-based metabolic interventions. ## Mechanism of Action The proposed biological actions of *Cissus quadrangularis* center on bone metabolism, inflammation, and metabolic regulation, though most mechanistic detail comes from laboratory and animal work rather than human studies. * **Bone-building (osteoanabolic) effects:** Stem extracts have been shown in cell and animal models to increase the activity and differentiation of osteoblasts (the cells that build new bone) and to boost markers of bone formation such as alkaline phosphatase and collagen deposition. In human osteoblast-like cells, the extract raised components of the IGF-1 system (insulin-like growth factor 1, a hormone that drives tissue growth and bone formation), offering one candidate pathway for its traditional "bone-setting" use. * **Reduced bone breakdown (anti-osteoclastic) effects:** Preclinical work indicates the plant can inhibit RANKL-induced osteoclastogenesis — the formation of osteoclasts, the cells that break down bone — through modulation of the immune signaling that drives bone loss after estrogen decline. By tipping the balance away from resorption and toward formation, the extract is thought to support bone density in models of estrogen-deficiency osteoporosis. * **Anti-inflammatory and antioxidant effects:** The plant is rich in flavonoids, triterpenoids, and plant sterols (phytosterols) that act as antioxidants and dampen pro-inflammatory signaling molecules (cytokines). This is the leading proposed explanation for the reductions in joint pain and swelling seen in animal arthritis models and in exercise-trained adults. * **Metabolic and adipose effects:** In a human adipose-cell study, the extract increased UCP1 (uncoupling protein 1, a protein that helps fat cells burn energy as heat), suggesting a "browning" of white fat as one route to its observed effects on waist circumference. Animal work also points to improved insulin signaling via activation of the AdipoR1 receptor (a docking site for the fat-derived hormone adiponectin) and reduced fat accumulation. * **Competing mechanistic views:** Because most positive mechanistic findings come from concentrated extracts in cells and rodents, a competing interpretation is that effects observed in vitro may not translate to the doses and bioavailability achievable from oral human supplements. Poor absorption of the plant's larger molecules is cited as a reason that strong laboratory signals have produced only modest and inconsistent human outcomes, motivating ongoing work on improved delivery formulations. ## Historical Context & Evolution * **Original intended use:** *Cissus quadrangularis* has been used for centuries in Ayurvedic and traditional African medicine, most prominently as a treatment to accelerate the healing of bone fractures — reflected in names such as Hadjod ("bone joiner") and Asthisamharaka ("that which prevents the destruction of bone"). It was also applied traditionally for conditions including hemorrhoids (swollen veins around the anus), gout (a painful joint condition caused by uric-acid crystals), digestive complaints, and menstrual disorders. * **Why it came to be considered for health optimization:** As laboratory analysis identified its content of flavonoids, plant sterols, and steroid-like compounds with anti-inflammatory and bone-active properties, the plant attracted attention from the sports-nutrition and bone-health markets. Early human and animal reports of faster fracture healing and reduced joint pain, combined with a clean short-term safety record, drove its adoption as a standalone supplement and as an ingredient in weight-management blends. * **Actual historical findings:** Mid-20th-century Indian research described accelerated fracture healing and increased bone-forming activity in animals given the extract, and later human reports in maxillofacial and limb fractures echoed these observations. Weight-management interest grew from double-blind trials of combination products (notably with *Irvingia gabonensis*) reporting reductions in weight and blood lipids. * **Standing of the historical research:** The early fracture-healing studies are not "debunked," but they were generally small, used non-standardized extracts, and often lacked rigorous controls; modern systematic reviews therefore treat their findings as promising but low-certainty rather than established. The reader can weigh the consistent direction of the traditional and early data against the methodological limits that keep current evidence graded as weak. * **Evolution of scientific opinion:** Opinion has shifted from uncritical acceptance of traditional fracture-healing claims toward a more cautious, evidence-graded view in which bone and joint signals are seen as plausible but unconfirmed, weight-management effects are attributed mainly to combination products, and the need for larger, well-standardized trials is emphasized. What changed was not a reversal of the early findings but the application of stricter trial standards that exposed how thin the high-quality human evidence remains. ## Expected Benefits The benefits below are framed for risk-aware adults seeking to support bone, joint, and metabolic health rather than for treatment of diagnosed disease in the general population. ### Medium 🟩 🟩 #### Fracture-Healing and Bone-Pain Support Pooled randomized-trial data indicate that *Cissus quadrangularis* can reduce pain and support recovery in bone fractures, an effect consistent with its traditional "bone-setter" use and with preclinical osteoanabolic findings. The 2017 meta-analysis of nine trials found significant benefit for bone-fracture pain, and a 2026 narrative review concluded the plant accelerates fracture healing and reduces bone pain in maxillofacial and mandibular fractures without major safety concerns. Certainty is limited by small, heterogeneous trials using non-standardized extracts, so this is best viewed as a supportive rather than primary intervention. **Magnitude:** Meta-analysis reported significant reduction in bone-fracture pain versus comparators; individual trials describe faster radiographic healing, though effect sizes are not consistently quantified. #### Joint-Pain Reduction in Active Adults For health- and longevity-oriented adults who train regularly, the plant's anti-inflammatory compounds may reduce exercise-related joint pain. A 2013 pilot study in 29 exercise-trained men reported a roughly 31% drop in total WOMAC joint-pain scores after eight weeks at 3,200 mg daily, and animal arthritis models show reduced inflammation and cartilage protection. The main limitation is that the key human study was uncontrolled (no placebo group), so part of the improvement may reflect placebo or regression effects. **Magnitude:** ~31% reduction in self-reported total joint-pain score over 8 weeks in a single uncontrolled pilot study. ### Low 🟩 #### Weight and Waist-Circumference Reduction Several trials, mostly of combination products, report reductions in body weight and central fat with *Cissus quadrangularis*. A human randomized trial found significant decreases in waist and hip circumference over eight weeks alongside increased fat-cell UCP1 expression, and a broad 2020 herbal-weight-loss meta-analysis flagged the plant among agents showing statistically and clinically significant weight loss in a small number of studies. A relevant conflict of interest applies here: much of the combination-product weight-loss evidence (notably the *Irvingia*–*Cissus* trials) was generated or funded by the product's commercial developer (Gateway Health Alliances), which has a direct financial interest in a favorable result, and the major emerging metabolic trials are likewise industry-sponsored. The evidence is downgraded because the strongest results come from these commercially developed combination formulas (making the individual contribution unclear) and the standalone trials are few and methodologically weak. **Magnitude:** Pooled estimate from combination-product trials showed about -5 kg body weight versus placebo; standalone trial showed significant waist-circumference reduction over 8 weeks. #### Improved Blood Lipids and Fasting Glucose In trials of combination products, *Cissus quadrangularis* has been associated with improvements in cholesterol, triglycerides, and fasting blood sugar, with mechanistic support from animal studies showing better insulin signaling and reduced gluconeogenesis (the body's internal production of glucose). As with weight loss, the metabolic benefits are drawn largely from combination formulas rather than isolated extract, limiting how confidently they can be attributed to the plant alone. **Magnitude:** Combination-product meta-analysis reported reductions of roughly -14 mg/dL LDL, -38 mg/dL triglycerides, and -10 mg/dL fasting glucose versus placebo. ### Speculative 🟨 #### Antioxidant and General Anti-Inflammatory Support The plant's flavonoids and phytosterols show antioxidant and anti-inflammatory activity in laboratory systems, leading to proposals that regular use could provide broad, low-grade anti-inflammatory support relevant to healthy aging. This benefit rests on mechanistic and animal data only; no controlled human trials test general anti-inflammatory or longevity outcomes, so it remains hypothetical. #### Cardiometabolic and Vascular Protection Animal studies report improved blood-vessel function, reduced blood pressure, and protection against diabetic heart and kidney changes via reduced oxidative stress and modulation of the renin-angiotensin system (a hormone network that controls blood pressure and fluid balance). These findings are intriguing for longevity-minded users but are entirely preclinical, with no human cardiovascular outcome data. ## Benefit-Modifying Factors * **Baseline bone status:** The clearest benefits appear in people with active bone repair needs (recent fractures) or early bone loss; randomized data in postmenopausal osteopenia show the extract stabilizes bone-turnover markers and delays loss without producing short-term gains in bone density, suggesting larger benefit where remodeling demand is high. * **Sex and menopausal status:** Several mechanistic and animal studies focus on estrogen-deficiency models, and human bone trials include postmenopausal women, so women in or after menopause may be a particularly relevant group; the joint-pain pilot study, by contrast, enrolled only men, leaving sex-specific joint effects uncertain. * **Age:** Older adults at the upper end of the target range, who face higher rates of bone loss and joint wear, are the population most likely to have a meaningful remodeling target, though they also tend to take more concurrent medications that could interact. * **Extract standardization and formulation:** Benefits vary widely with extract type and dose because products differ in their content of active compounds; improved-bioavailability formulations (e.g., self-emulsifying delivery systems) are being developed specifically because poor absorption appears to blunt benefit. * **Combination versus standalone use:** Metabolic and weight benefits are strongest in combination products, so the presence of co-ingredients (such as *Irvingia gabonensis*) can substantially modify the observed effect of a *Cissus quadrangularis* supplement. ## Potential Risks & Side Effects Risks are framed for proactive adults considering self-directed supplementation; *Cissus quadrangularis* has a generally favorable short-term safety record, with most concerns being mild or theoretical. ### Low 🟥 #### Gastrointestinal Upset The most commonly reported side effects are mild and digestive — including gas (flatulence), diarrhea, dry mouth, and stomach discomfort — typically occurring early in use and often resolving with continued intake or dose reduction. These are consistent across reviews and the clean safety record reflects that no serious adverse events were reported in pooled trial data. **Magnitude:** Reported in a minority of users across trials; generally mild and self-limiting, with no serious gastrointestinal events recorded in meta-analyses. #### Headache and Insomnia Some users and trial participants report headache, drowsiness, or trouble sleeping, particularly at higher doses. The mechanism is unclear and the frequency low, but these effects are noted in supplement reviews and warrant attention for people sensitive to stimulating or sedating agents. **Magnitude:** Infrequent; described qualitatively in user reports and reviews rather than quantified in controlled trials. ### Speculative 🟨 #### Thrombocytopenia in Immunocompromised Use A single case report described thrombocytopenia (an abnormally low platelet count, which raises bleeding risk) in a kidney-transplant recipient taking *Cissus quadrangularis*, raising a theoretical concern about blood-cell or immune effects in vulnerable patients. As an isolated report in a heavily medicated transplant patient, causation is unestablished, but it flags caution for immunosuppressed or transplant populations. #### Effects in Pregnancy and Hormonal Sensitivity Because the plant contains steroid-like and possibly estrogen-active compounds and has traditional use affecting menstruation, there is a theoretical concern for use during pregnancy, breastfeeding, or in hormone-sensitive conditions. No controlled safety data exist for these groups, so the concern is precautionary rather than evidence-based. #### Blood-Sugar and Blood-Pressure Lowering Given signals that the plant can lower fasting glucose and (in animals) blood pressure, there is a theoretical risk of additive lowering when combined with glucose- or pressure-lowering treatment. This is mechanistically plausible but not documented as a clinical event in humans. ## Risk-Modifying Factors * **Genetic and metabolic individuality:** No specific gene variants are established as modifying the plant's risk profile, but individuals with inherited bleeding tendencies or platelet disorders may warrant extra caution given the isolated thrombocytopenia report. * **Baseline biomarkers:** People with already-low fasting glucose or blood pressure, or those on medications targeting these, face a higher theoretical chance of additive lowering and should monitor accordingly. * **Sex and hormonal status:** Because some constituents may have estrogen-like activity, women who are pregnant, breastfeeding, or have hormone-sensitive conditions represent a higher-uncertainty group for whom safety data are absent. * **Pre-existing conditions:** Immunosuppressed individuals (e.g., transplant recipients), people with bleeding disorders, and those with poorly controlled diabetes are the subgroups in whom the otherwise mild risk profile becomes more relevant. * **Age and polypharmacy:** Older adults at the upper end of the target range are more likely to take multiple medications, increasing the chance of interactions even though the plant's intrinsic toxicity appears low (animal LD₅₀ above 3,000 mg/kg). ## Key Interactions & Contraindications * **Antidiabetic drugs:** Because *Cissus quadrangularis* may lower fasting blood sugar, combining it with glucose-lowering agents (metformin, sulfonylureas such as glipizide, insulin) could theoretically cause additive hypoglycemia (low blood sugar). **Severity:** caution. **Clinical consequence:** excessive blood-sugar lowering. **Mitigation:** monitor blood glucose and adjust antidiabetic dosing as needed. * **Antihypertensive drugs:** Animal data suggest blood-pressure-lowering activity, so co-use with blood-pressure medications (ACE inhibitors such as lisinopril, ARBs such as losartan, calcium-channel blockers) could in theory add to their effect. **Severity:** caution. **Clinical consequence:** hypotension (abnormally low blood pressure). **Mitigation:** monitor blood pressure when starting. * **Immunosuppressants:** Given the isolated thrombocytopenia report in a transplant recipient, use alongside immunosuppressants (tacrolimus, mycophenolate, ciclosporin) is best avoided without specialist oversight. **Severity:** caution to avoid. **Clinical consequence:** possible low platelet count or unpredictable immune effects. **Mitigation:** avoid in transplant/immunosuppressed patients unless monitored. * **Over-the-counter medications:** No specific over-the-counter interactions are well documented; however, combining with over-the-counter anti-inflammatory agents (NSAIDs such as ibuprofen) adds overlapping anti-inflammatory load without established benefit, and concurrent use with over-the-counter blood-sugar or weight-loss aids could compound metabolic effects. **Severity:** monitor. **Clinical consequence:** additive effects. **Mitigation:** avoid stacking similar-acting products. * **Supplement interactions:** It is commonly combined with *Irvingia gabonensis* in weight products, which amplifies metabolic effects; co-use with other glucose-lowering supplements (berberine, chromium) or blood-pressure-lowering supplements may be additive. **Severity:** caution. **Clinical consequence:** additive metabolic lowering. **Mitigation:** introduce one agent at a time and monitor. * **Additive supplements to note:** Supplements that also lower blood sugar (berberine, cinnamon, alpha-lipoic acid) or that support bone turnover (calcium, vitamin D, vitamin K2) may have additive effects with *Cissus quadrangularis* and are relevant to consider when stacking. * **Populations who should avoid or use caution:** pregnant and breastfeeding women (no safety data; possible hormonal activity); transplant recipients and immunosuppressed individuals (case-report concern); people with bleeding disorders or scheduled surgery (theoretical platelet effect — consider stopping at least 2 weeks before surgery); and those with hormone-sensitive conditions, given possible estrogen-like constituents. ## Risk Mitigation Strategies * **Start at a low dose and titrate:** To reduce the mild gastrointestinal effects (gas, diarrhea, stomach discomfort) reported early in use, begin near the lower end of typical dosing (e.g., 500 mg daily) and increase gradually toward 1,000–3,200 mg daily over 1–2 weeks if tolerated. * **Monitor blood glucose and blood pressure:** Because the plant may lower fasting blood sugar and (in animals) blood pressure, people on antidiabetic or antihypertensive treatment should check glucose and blood pressure when starting and after any dose increase to catch additive lowering early. * **Avoid in higher-risk populations:** To prevent the rare but serious concern of thrombocytopenia and unknown hormonal effects, transplant recipients, immunosuppressed individuals, and pregnant or breastfeeding women should avoid use unless supervised by a clinician. * **Pause before surgery:** Given the theoretical effect on platelets and the isolated bleeding-related report, discontinuing at least 1–2 weeks before any planned surgery reduces potential bleeding risk. * **Choose standardized, tested products:** To avoid contamination and unpredictable dosing that could increase side-effect risk, select extracts standardized to a stated active content (e.g., a defined ketosteroid or extract ratio) and verified by third-party testing. ## Therapeutic Protocol * **Standard supplementation pattern:** As used in supplement practice and reflected in human trials, *Cissus quadrangularis* stem extract is typically taken at 500–3,200 mg daily of standardized extract; bone- and joint-focused use clusters around 500–1,000 mg of concentrated extract, while the exercise joint-pain pilot used 3,200 mg daily of a defined extract. * **Competing approaches:** A conventional approach uses *Cissus quadrangularis* as a standalone bone/joint support, whereas an integrative weight-management approach uses it within combination formulas (notably with *Irvingia gabonensis*); the bone-health literature also positions it as a possible adjunct during bisphosphonate "drug holidays" rather than a replacement for established osteoporosis therapy. Neither approach is established as superior. * **Originators of approaches:** The combination weight-loss approach was popularized by the Gateway Health Alliance trials of an *Irvingia*–*Cissus* product; the osteoporosis-adjunct framing is advanced in recent academic reviews (e.g., Manocchio et al., 2026) rather than by a single clinic. * **Best time of day:** No strong timing data exist; products are commonly taken with food to reduce gastrointestinal upset, and splitting doses across the day is typical for higher total intakes. * **Half-life:** The human pharmacokinetics and half-life of the plant's active constituents are poorly characterized; bioavailability of its larger molecules appears low, which is why divided daily dosing and improved-delivery formulations are used. * **Single versus split dosing:** For higher totals (e.g., ≥1,600 mg), dosing is generally split into two or three administrations with meals; lower bone-support doses are often taken once or twice daily. * **Genetic considerations:** No pharmacogenetic variants are established for dose selection; individualization is currently based on tolerance and goals rather than genotype. * **Sex-based differences:** Bone-health trials emphasize postmenopausal women while the main joint-pain study enrolled only men, so optimal dosing by sex is not defined; women using it for bone support follow the same general dose ranges. * **Age-related considerations:** Older adults at the upper end of the target range may benefit most for bone remodeling but should start low and monitor for interactions given more frequent polypharmacy. * **Baseline biomarkers:** Baseline bone-turnover markers and, where relevant, fasting glucose and lipids help define a target and a way to gauge response before and during use. * **Pre-existing conditions:** Diabetes, hypertension, and bone disorders are the conditions most likely to shape whether and how the supplement is used, both for potential benefit and for interaction monitoring. ## Discontinuation & Cycling * **Lifelong versus short-term use:** Use is typically goal-bounded rather than lifelong — for example, a defined course around fracture healing (weeks to a few months) or a trial period of 8–24 weeks for joint or metabolic goals, after which response is reassessed. * **Withdrawal effects:** No withdrawal syndrome has been described; the plant is not known to produce dependence or rebound effects on stopping. * **Tapering:** No tapering protocol is required or established; it can generally be stopped without a gradual reduction. * **Cycling:** There is no evidence that cycling is needed to maintain efficacy; some users cycle empirically (e.g., on for several weeks, then off) but this is not supported by data. * **Reassessment on stopping:** Because benefits for joint and metabolic goals may fade after discontinuation, users typically reassess symptoms and relevant markers after stopping to decide whether to resume. ## Sourcing and Quality * **Standardization to actives:** Look for extracts standardized to a defined active fraction (commonly expressed as a percentage of ketosteroids or a stated extract ratio such as 20:1), since unstandardized stem powders vary widely in potency and likely explain inconsistent trial results. * **Third-party testing:** Choose products independently tested (e.g., by an accredited laboratory or carrying a recognized quality seal) for identity, potency, and contaminants such as heavy metals and microbial load, which is important for a wild- or field-harvested botanical. * **Plant part and species verification:** Confirm the product specifies the aerial/stem part of *Cissus quadrangularis* (Vitaceae) and verifies species identity, as related Cissus species and adulterants exist in the supply chain. * **Reputable brands and formulations:** Established sports-nutrition and supplement brands that publish certificates of analysis, and emerging branded standardized extracts, are preferable to generic bulk powders of unknown origin. * **Formulation type:** Where bioavailability is a concern, newer self-emulsifying or enhanced-delivery formulations may offer more consistent absorption than raw powder, though they are not yet validated in large trials. ## Practical Considerations * **Time to effect:** Joint-pain and metabolic studies generally run 8 weeks, and bone trials extend to 24 weeks, so a realistic trial period is roughly 8–24 weeks before judging response. * **Common pitfalls:** Frequent mistakes include using unstandardized powders of unknown potency, attributing combination-product results to standalone extract, expecting rapid bone-density gains (which short trials do not show), and under-dosing relative to the amounts used in studies. * **Regulatory status:** In the United States it is sold as a dietary supplement and is not approved or evaluated by the Food and Drug Administration (FDA) for treating any condition; quality and labeling accuracy therefore vary by manufacturer. * **Cost and accessibility:** It is inexpensive and widely available online and in supplement stores, so cost and access are not significant barriers. * **Realistic expectations:** It is best framed as a low-risk, modest-benefit adjunct for bone, joint, or metabolic support rather than a primary therapy, with the strongest signals tied to specific contexts (fracture recovery, exercise joint pain, combination weight products). ## Interaction with Foundational Habits * **Sleep:** The interaction with sleep is largely indirect and uncertain; a minority of users report drowsiness or insomnia, so anyone noticing sleep disruption may prefer earlier-day dosing, but there is no established mechanism linking the plant to improved or worsened sleep. * **Nutrition:** The interaction with nutrition is direct in that taking the extract with food reduces gastrointestinal upset, and its bone benefits are best supported alongside adequate dietary calcium, vitamin D, and protein; no nutrient depletions are documented. * **Exercise:** The interaction with exercise is potentiating for the joint-comfort goal — the main human joint-pain study was specifically in exercise-trained men, suggesting the plant's anti-inflammatory action is most relevant for active people, and there is no evidence it blunts training adaptations. * **Stress management:** The interaction with stress management is indirect and not well studied; while reduced inflammation could theoretically support resilience, no human data link *Cissus quadrangularis* to cortisol or stress-response measures, so any effect is unproven. ## Monitoring Protocol & Defining Success Baseline assessment helps establish a personal starting point before beginning supplementation, especially for those using the plant for bone or metabolic goals or taking interacting medications. Ongoing monitoring is generally light given the favorable safety profile: a reasonable cadence is a baseline check, reassessment at about 8 weeks for joint or metabolic goals, and at roughly 3–6 months for bone-focused use, then every 6–12 months if continued. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|----------------| | Fasting blood glucose | 70–85 mg/dL | Detects additive blood-sugar lowering and tracks metabolic benefit | Fasting required; especially relevant if on antidiabetic drugs | | HbA1c | < 5.4% | Confirms sustained glycemic effect over time | Glycated hemoglobin, a 3-month average of blood sugar; no fasting needed; best for metabolic-goal users | | Lipid panel (LDL, triglycerides, total/HDL) | LDL < 100 mg/dL; triglycerides < 90 mg/dL | Tracks the lipid improvements seen with combination products | 9–12 h fasting preferred; pair with glucose | | Bone turnover markers (e.g., CTX and P1NP) | Mid-reference for age/sex | Reflects effect on bone remodeling, which trials show before density changes | CTX and P1NP are markers of bone breakdown and formation; morning, fasting; CTX is diurnal and food-sensitive | | Serum parathyroid hormone (PTH) | 15–45 pg/mL | Meta-analysis shows the plant can raise PTH; useful to watch in bone users | PTH is a hormone regulating calcium and bone; draw with calcium and vitamin D for context | | 25-hydroxyvitamin D | 40–60 ng/mL | Ensures adequate vitamin D to support any bone benefit | Conventional "sufficient" is ≥ 30 ng/mL; functional target is higher | | Platelet count | 150–400 ×10⁹/L | Screens for the rare thrombocytopenia concern, mainly in higher-risk users | Part of a standard complete blood count | Qualitative markers help capture day-to-day response that labs may miss: * Joint pain and stiffness during and after exercise * Recovery time and swelling after training or injury * Energy levels and general well-being * Digestive comfort (to detect early gastrointestinal side effects) * For bone-healing use, functional recovery and pain at a fracture site ## Emerging Research * **Ongoing metabolic trial (appetite hormones):** A study is testing aqueous extracts of *Cissus quadrangularis* and *Dichrostachys glomerata* on GLP-1 (a gut hormone that regulates appetite and blood sugar) and DPP-4 activity in 248 overweight and obese adults — [NCT06827002](https://clinicaltrials.gov/study/NCT06827002), Phase 1/2, primary endpoints GLP-1 level and DPP-4 activity. * **Combination metabolic-health product:** A planned trial of a multi-ingredient product containing *Cissus quadrangularis* (Glucocil) will assess effects on HbA1c and metabolic health in 100 people with prediabetes and type 2 diabetes — [NCT06496893](https://clinicaltrials.gov/study/NCT06496893), primary endpoint HbA1c. * **Weight-management blend (MB-1):** A planned placebo-controlled trial will evaluate a *Cissus*-containing product (MB-1) on body weight and body mass index in 100 overweight and obese adults — [NCT07363148](https://clinicaltrials.gov/study/NCT07363148). * **Bioavailability-focused formulations:** Future research is expected to clarify whether improved-delivery formulations (self-emulsifying systems and nanocomposites) raise absorption enough to convert strong preclinical bone signals into confirmed human outcomes, as proposed by Garg et al., 2024 — [PMID 38730121](https://pubmed.ncbi.nlm.nih.gov/38730121/). * **Bone-density endpoints in osteoporosis:** A key open question, raised in the 2025 bone-biomarker meta-analysis and the 2026 osteoporosis review, is whether longer, larger, standardized trials can demonstrate actual bone-mineral-density gains rather than only changes in turnover markers — [PMID 40707943](https://pubmed.ncbi.nlm.nih.gov/40707943/). * **Counter-signal on parathyroid hormone:** Emerging meta-analytic data that the plant raises parathyroid hormone could weaken the bone-health case if sustained elevation proves catabolic, illustrating that not all new evidence points in a favorable direction — [PMID 40707943](https://pubmed.ncbi.nlm.nih.gov/40707943/). ## Conclusion *Cissus quadrangularis* is a traditional medicinal vine, long used to help mend broken bones, that has become a low-cost supplement marketed for bone strength, joint comfort, and weight management. Its plant compounds appear to build bone-forming activity, calm inflammation, and nudge fat cells toward burning energy, which gives a plausible basis for the uses people seek. The human evidence is real but modest. Pooled trials suggest it can ease fracture-related and exercise-related joint pain, and combination products show reductions in weight, blood fats, and blood sugar. Yet most studies are small, short, and use poorly standardized extracts, and reviewers consistently rate the overall certainty as low; benefits for body weight and metabolism lean heavily on multi-ingredient formulas rather than the plant alone, and much of that weight-loss evidence comes from trials run or paid for by the companies selling the products, which is a clear source of bias. Notably, it has not yet been shown to raise bone density over the short term. Safety over the short term looks favorable, with mostly mild digestive complaints and only rare, isolated concerns in vulnerable users. The picture that emerges is of a generally well-tolerated, inexpensive add-on with promising but unconfirmed effects, where the traditional reputation has outpaced the high-quality human evidence, and the strongest signals remain tied to specific contexts rather than to broad, well-established benefit. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**